达格列净在血糖控制不佳肥胖2型糖尿病患者临床治疗中的效果观察

Effect of Dapagliflozin in the Treatment of Obese Diabetes Mellitus Type 2 Patients with Poor Glycemic Control

目的探讨达格列净在血糖控制不佳肥胖2型糖尿病患者临床治疗中的效果。方法选择2022年10月—2023年10月该院收治的104例肥胖2型糖尿病患者为研究对象,按随机数字表法将其分为对照组与观察组,各52例。对照组采用二甲双胍缓释片治疗,观察组采用二甲双胍缓释片联合达格列净治疗。比较两组血糖指标、血脂指标、胰岛功能指标、身体质量指数、腹围指标及不良反应发生情况。结果治疗前,两组血糖指标、血脂指标、胰岛功能指标、身体质量指数及腹围指标比较,组间差异无统计学意义(P>0.05):治疗后,观察组空腹血糖、糖化血红蛋白、总胆固醇、甘油三酯、低密度脂蛋白胆固醇、胰岛素抵抗指数、身体质量指数及腰围指标水平均低于对照组,胰岛β细胞功能指数、空腹胰岛素、空腹C肽水平均高于对照组,组间差异有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论达格列净治疗效果优于利格列汀,其降血糖、血脂及改善胰岛功能、减轻患者体重及缩小腹围的作用更佳,且安全性良好。

Objective To investigate the clinical effect of dapagliflozin in the treatment of obese diabetes mellitus type 2 patients with poor blood glucose control.Methods A total of 104 obese patients with diabetes mellitus type 2 admitted to the the hospital from October 2022 to October 2023 were selected as the research objects.According to the random number table method,they were divided into a control group and an observation group,with 52 cases in each group.The control group was treated with metformin sustained-release tablets,and the observation group was treated with metformin sustained-release tablets combined with dapagliflozin.The blood glucose index,blood lipid index,islet function index,body mass index,abdominal circumference index and occurrence of adverse reactions were compared between the two groups.Results There were no significant differences in blood glucose,blood lipid,islet function,body mass index and abdominal circumference between the two groups before treatment(P>0.05).After treatment,the levels of fasting plasma glucose,glycosylated hemoglobin,total cholesterol,triglyceride,low-density lipoprotein cholesterol,insulin resistance index,body mass index and waist circumference in the observation group were lower than those in the control group,the levels of isletβcell function index,fasting insulin and fasting C-peptide were higher than those in the control group,the differences between the two groups were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Dapagliflozin is more effective than linagliptin in reducing blood glucose,blood lipid,improving islet function,reducing body weight and abdominal circumference,and it is more safe.